Tax exemption for branded life-saving drugs depends on substance and ingredients, not brand name; binding directions were invalid.

Brand-name life-saving drugs were not excluded from exemption merely because their market names differed from the drugs listed in the notification; the decisive inquiry was whether the branded product was, in substance, the same exempted drug, with the same ingredients and therapeutic value. The use of a different form or packaging did not by itself defeat exemption. The Commissioner could not issue binding directions compelling assessing authorities to deny exemption, because exemption claims had to be decided independently on the evidence. Notices and assessments based on such rigid instructions were therefore unsustainable, and fresh consideration of the exemption claims was required.

---

---

Issues: (i) Whether life-saving drugs sold under brand names were excluded from exemption under the notification dated 31 March 1992 merely because their market names did not match the names listed in the notification. (ii) Whether the Commissioner, Sales Tax, could issue directions or guidance binding assessing authorities to deny exemption to branded life-saving drugs.

Issue (i): Whether life-saving drugs sold under brand names were excluded from exemption under the notification dated 31 March 1992 merely because their market names did not match the names listed in the notification.

Analysis: The notification granted exemption to specified life-saving drugs under section 4(a) of the U.P. Sales Tax Act, 1948. The Court read the notification in the light of its object, namely, to make such drugs available at cheaper rates, and held that the relevant enquiry was whether the goods sold in brand names were in substance the same exempted life-saving drugs. The use of the words "that is to say" limited the class of exempted goods to the enumerated drugs, but did not justify excluding a product otherwise consisting of the same ingredients and retaining the same therapeutic value merely because it was marketed under a brand name or in a different form such as capsule, oral suspension or injection. The Court applied the common parlance and contextual approach to taxation and exemption provisions and held that the form or brand name by itself was not decisive.

Conclusion: Brand-name life-saving drugs were not automatically excluded from exemption; if the assessing authority found that the branded product contained the same exempted ingredients and had no additional non-exempt compound altering its therapeutic value, exemption could still be granted.

Issue (ii): Whether the Commissioner, Sales Tax, could issue directions or guidance binding assessing authorities to deny exemption to branded life-saving drugs.

Analysis: The Court held that the Commissioner had no authority to issue directions, instructions, guidelines or messages overriding the notification or pre-empting the independent decision-making of the assessing authority. Such communication would interfere with judicial discretion in assessment proceedings, especially where the authority had to examine evidence and decide whether the branded product answered the description of the exempted drug. The Court further held that notices and assessment orders based on such a rigid instruction were vitiated because the authorities had not applied their own mind to the exemption claim.

Conclusion: The Commissioner could not bind subordinate assessing authorities by such directions, and the resulting notices and completed assessments could not stand on that basis.

Final Conclusion: The writ petitions succeeded, the assessees were to be given a fresh opportunity to respond, and the assessing authority was required to decide exemption claims independently on the basis of the ingredients and components of the drugs.

Ratio Decidendi: In interpreting a tax exemption notification, the substance of the goods, their ingredients and commercial identity must prevail over the mere brand name, and an executive instruction cannot curtail the independent statutory discretion of the assessing authority.

---